1. Yamaji K, Räber L, Zanchin T, Spitzer E, Zanchin C, Pilgrim T, et al. Ten-year clinical outcomes of first-generation drug-eluting stents: the sirolimus-eluting vs. paclitaxel-eluting stents for coronary revascularization (SIRTAX) VERY LATE trial. Eur Heart J. 2016;37(45):3386–95.
2. Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation. 2019;139(3):325–33.
3. Stefanini GG, Alfonso F, Barbato E, Byrne RA, Capodanno D, Colleran R, et al. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EuroIntervention. 2020;16(11):e875–90.
4. Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2020;75(6):590–604.
5. Pareek M, Madsen M, Warnakula Olesen KK, Okkels Jensen L, Høj Christiansen E, Dalby Kristensen S, et al. Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study. EuroIntervention. 2019;15(11):e1022–4.